Astellas, Daiichi Move Ahead With Factor Xa Programs
Astellas and Daiichi Sankyo both are on track to proceed to Phase III for their respective oral Factor Xa inhibitors, the companies indicated in second quarter earnings presentations on Nov. 7
Astellas and Daiichi Sankyo both are on track to proceed to Phase III for their respective oral Factor Xa inhibitors, the companies indicated in second quarter earnings presentations on Nov. 7